AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Dec 2, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia …
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 …
Patients Taking AUSTEDO XR® (deutetrabenazine) extended …
Sep 20, 2025 · Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data …
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Pronunciation: aw-STED-oh Generic name: deutetrabenazine Dosage form: Austedo tablets (6 mg, 9 mg, 12 mg), Austedo XR (6 mg, 12 mg, 18 mg, 24 mg, 30 mg, 36 mg, …
Austedo | European Medicines Agency (EMA)
Overview On 19 June 2025, the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion, recommending the granting of a marketing authorisation for the …
Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO …
Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of …
Reported Saturday, Teva Reports Patients With Tardive Dyskinesia …
Sep 22, 2025 · Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) …
Aug 1, 2025 · References Austedo/Austedo XR (deutetrabenazine) [prescribing information]. Parsippany, NJ: Teva Neuroscience, Inc; February 2025. Indirect tolerability compar al. Long …
Austedo XR Ratings & Reviews by Doctors | Uses & Side Effects
Austedo XR is deemed effective for managing symptoms of Huntington's disease and tardive dyskinesia, although it does not cure either condition and may not work uniformly for all …
Looking at the Narrative for Teva After Evolving Price Targets and ...
5 days ago · Teva issued long term guidance for Austedo, targeting $2.5 billion in revenue by 2027 and peak sales of more than $3 billion. This underscores the medicine's central role in …